Why the study?
Heart failure is linked with polypharmacy, but the incidence rate of mortality in heart failure patients with polypharmacy is poorly studied.
Does polypharmacy increase the risk of all-cause mortality in incident hospitalized heart failure patients?
Does polypharmacy increase the risk of all-cause mortality in incident hospitalized heart failure patients?
Overall polypharmacy (≥ 10 drugs), but not specifically CV or non-CV polypharmacy, is associated with an increased risk of 1-year mortality in patients recently hospitalized for heart failure.
No takes yet. Share an insight, caveat, or question.
Polypharmacy was associated with higher mortality in hospitalized HF patients; leaves open whether deprescribing improves outcomes.
Perreault et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: